JCF Heart Failure Year-In-Review 2023… Shaping the Future of Heart Failure

Journal of Cardiac Failure, Journal Year: 2024, Volume and Issue: 30(1), P. 1 - 3

Published: Jan. 1, 2024

Language: Английский

---

Ironing Out Heart Failure: Clarifying the Role of Intravenous Iron Therapy

The Hematologist, Journal Year: 2024, Volume and Issue: 21(1)

Published: Jan. 1, 2024

Language: Английский

---

Considerations Regarding Management of Heart Failure in Older Adults

Cardiology in Review, Journal Year: 2024, Volume and Issue: unknown

Published: Feb. 29, 2024

Understanding noncardiovascular comorbidities and geriatric syndromes in elderly patients with heart failure (HF) is important as the average age of population increases. Healthcare professionals need to consider these complex dynamics when managing older adults HF, especially those than 80. A number small studies have described associations between HF major domains. With information on patients’ cognitive, functional decline, ability adhere therapy, physicians can plan for individualized treatment goals recommendations patients.

Language: Английский

---

Iron replacement therapy in heart failure: Contextualizing the results of the HEART‐FID trial

European Journal of Heart Failure, Journal Year: 2024, Volume and Issue: 26(3), P. 537 - 539

Published: March 1, 2024

Language: Английский

---

Lung ultrasound at discharge predicts outcomes in heart failure: a pilot study

Journal of Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: March 20, 2024

Letter to the Editor Lung ultrasound (LUS) is a valid tool for assessment of pulmonary congestion in patients with heart failure. However, whether LUS predicts clinical outcomes failure has yet be widely validated. We investigated presence an association between grade residual assessed by at hospital discharge and 3-month Materials methods A prospective observational study was conducted on 85 who presented during hospitalization Cardiac Rehabilitation Unit Federico II University Hospital Naples from March 2021 until September 2022. The accordance principles Declaration Helsinki. All participants signed informed consent before participating. performed using score as indicator congestion. To calculate score, both hemithoraxes were topographically divided into six regions, each which assigned 0 3: 0, 0–3 B-lines; 1, >3 2, confluent 3, white lung.1 Clinical, echocardiographic, laboratory values collected admission discharge. CKD defined eGFR below 60 ml/min/1.73 m2 CKD-EPI formula. Remote monitoring through dedicated phone calls 90 days after evaluate new-onset/worsening dyspnea, cardiovascular rehospitalization, angina, death causes. relationship available variables multivariable logistic regression model converging backward forward stepwise selection. Multicollinearity evaluated variance inflation factor. statistical analyses R (R Foundation). Two-sided P-value less than 0.05 considered significant. Results Baseline characteristics enrolled population are summarized Table 1. composed failure, 70.5% recovering acute myocardial infarction, 20.0% event 9.5% complex elective coronary revascularization. 1 - Variables Overall (N = 85) Age, year [median (IQR)] 71.00 (63.00, 76.00) Female sex (%) 29 (34.1) Hypertension 78 (91.8) Atrial fibrillation 11 (12.9) Type diabetes mellitus 30 (35.3) Chronic kidney disease 13 (15.3) obstructive 17 (20.0) Heart rate, bpm [mean (SD)] 69.72 (11.03) SBP, mmHg 121.22 (16.73) DBP, 69.92 (8.04) SPO2, % 96.11 (1.97) Hemoglobin, g/dl 11.86 (1.98) Sodium, mEQ/l 138.51 (2.88) eGFR, 67.94 (22.71) NT-proBNP, pg/ml 1277.00 (482.00, 2692.00) 2.00 (0.00, 4.00) Ejection fraction, 45.52 (10.56) Left atrial volume indexed, ml/m2 38.02 (14.70) TAPSE 19.95 (4.96) Pulmonary artery pressure 34.26 (10.20) Median age 71 years (63,76), 34.1% women, hypertension (91.8%) (35.3%) being most prevalent comorbidities. NT-proBNP [482.00, 2692.00], mean ejection fraction 45.52% ± 10.6% median 2 4.00). significantly different male [1.00 3.25)] female [3.00 (1.00, 5.00)] (P 0.032) [4.00 (2.00, 7.00)] without 4.00)] 0.004), not respect other baseline variables. At 3 months, 49 reported new-onset or worsening dyspnea; those, had concomitant 10 rehospitalization causes, died. Only five angina dyspnea. Univariable linear regressions showed significant (beta 0.10 per 500 increase, P 0.022), 0.82 0.049), left indexed BSA 0.65 0.027), −0.58 0.002), hemoglobin −0.61 0.004). Regarding outcome, higher scores associated composite causes [odds ratio (OR) 5.3, 95% confidence interval (95% CI) 1.1–39.6], dyspnea months (OR 5.5, CI 1.4–36.7, 0.037), but (Fig. 1).Fig. 1: On lung outcomes, right boxplot value reporting combined outcome.When outcome including ventricle PAPs, age, sex, remained 11.3, 2.0–97.8, 0.01), together 0.5, 0.3–0.87, < 0.01 every increase 10% fraction) PAPs 1.9, 1.8–9.8, 0.02). Comments Clinical been previously proven valuable predictor failure;2 however, best choice still debated.3 recent HFA position paper predischarge early postdischarge management hospitalized failure4 suggested that phase, multiparametric evaluation mandatory order minimize persistent optimize guideline-directed medical therapy. 28-site scanning approach fewer 5 B-lines optimal 15 acceptable evaluation. Rosano et al.5 vulnerable period immediately AHF, very events expected discharged complete relief congestion, this often early. In setting, cardiac rehabilitation unit further strengthens importance discharging patient possible decongestion achieved. easy, feasible, fast method adds base failure.6,7 correlation indicates ability select more fragile patients, like cardiorenal syndrome phenotype8 iron-deficiency phenotype,9 risk events. This proved its Albeit no found it should noted powered these so results only hypothesis-generating. As known literature,10,11 correlates mortality, high morbidity cost quality life; better easy-to-use methodologies such potential reduce number Acknowledgements Conflicts interest There conflicts interest.

Language: Английский

---

Iron Metabolic Biomarkers and the Mortality Risk in the General Population: A Nationwide Population-Based Cohort Study

Journal of the Endocrine Society, Journal Year: 2024, Volume and Issue: 8(6)

Published: April 1, 2024

Abstract Context Iron is an essential element in the human body and plays a critical role many physiological cellular processes. However, association between iron status risk of all-cause or cause-specific mortality has not been well-investigated. And it unclear whether metabolic biomarkers differs people with without diabetes mellitus (DM). Objective This work aimed to investigate associations general population, heterogeneities among population DM.. Methods A total 29 166 adults from National Health Nutrition Examination Survey (NHANES) III NHANES 1999 2010 were included, linkage Death Index December 31, 2019. Cox proportional-hazard models Fine-Gray subdistribution hazard used estimate outcomes. Results During median follow-up 18.83 years, 9378 deaths observed, including 3420 cardiovascular disease (CVD) 1969 cancer deaths. significant linear serum ferritin (SF) was observed overall those DM. J-shaped transferrin saturation (TSAT) CVD all populations. In compared first quartile (Q1) group, adjusted ratio (HR) (95% CI) for 1.07 (1.00-1.15), 1.05 (0.98-1.12), 1.13 (1.05-1.21) Q2, Q3, Q4 groups SF, while HR 0.94 (0.88-0.99), 0.92 (0.86-0.97), 0.93 (0.88-0.99) TSAT. individuals DM, SF 1.19 (1.03-1.37) 1.25 (1.05-1.48) mortality. HRs TSAT 0.76 (0.62-0.93) 1.47 (1.07-2.03) Conclusion metabolism abnormalities increase population. The significantly different which indicated tailored strategies homeostasis are needed.

Language: Английский

---

Analysis of Genes Involved in Oxidative Stress and Iron Metabolism in Heart Failure: A Step Forward in Risk Stratification

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: May 20, 2024

Introduction: Heart failure (HF) is a clinical syndrome characterized by cardinal symptoms that may be accompanied signs. It results from structural and/or functional abnormalities of the heart leading to elevated intracardiac pressures inadequate cardiac output at rest during exercise. The prevalence iron deficiency and anemia justifies current guidelines recommendation screening. Genes HP, ACE, MTHFR, HFE, CYBA are involved in oxidative mechanisms, metabolism, hematologic homeostasis. This study investigates contribution variants Hp1/2 (HP), I/D (ACE), C677T (MTHFR), C282Y H63D (HFE), C242T (CYBA) development HF, either independently or epistasis. Methods: We used database 389 individuals, 143 HF patients, 246 healthy controls. Genotypes were through PAGE electrophoresis, PCR, PCR-RFLP, multiplex-ARMS. Data analysis was performed with SPSS® 26.0 software (IBM Corp., Armonk, NY). Results: observed significant association between MTHFR gene predisposition. presence allele T genotype CT constituted risk, while CC granted protection. Epistatic interactions revealed risk II ACE genotypes (C282Y) HH (H63D) HFE gene. Risk also for 2-2 (HFE-H63D). Conclusion: concluded genes contribute susceptibility individually contributes clarification role mechanisms metabolism play physiopathology HF. is, therefore, step forward stratification personalized medicine.

Language: Английский

---

Challenges and opportunities in patients with adult congenital heart disease, a narrative review

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: May 30, 2024

Adult congenital heart disease Pregnancy Transition of care Challenges failure.

Language: Английский

---

Prognostic impact of iron deficiency in new‐onset chronic heart failure: Danish Heart Failure Registry insights

ESC Heart Failure, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 6, 2024

Abstract Aims Iron deficiency (ID) is prevalent in chronic heart failure (HF) but lacks a consensus definition. This study evaluates the prevalence and prognostic impact of ID using different criteria on all‐cause cardiovascular mortality, as well first hospitalization for HF patients with new‐onset HF. Methods In this nationwide registry‐based cohort, we explored four definitions ID: current European Society Cardiology (ESC) guidelines [ferritin <100 ng/mL or ferritin 100–299 transferrin saturation (TSAT) <20%], level ng/mL, TSAT < 20% serum iron ≤13 μmol/L. Patients were identified through Danish Heart Failure Registry. Results Of 9477 registered Registry from April 2003 to December 2019, observed rates ranging 35.8% 64.3% depending definition used. Among defined by μmol/L 20%, 26% 15.5%, respectively, did not meet ESC ID. Conversely, 11% meeting exhibited >13 > 20%. Regardless anaemia status, was associated mortality [non‐anaemic, hazard ratio (HR): 1.57, 95% confidence interval (CI): 1.30–1.89 HR: 1.47, CI: 1.24–1.73; anaemic, 1.22, 1.07–1.38 1.25, 1.09–1.44, respectively] (non‐anaemic, 2.21, 1.59–3.06 1.12–1.95; 1.37, 1.11–1.69 1.28, 1.02–1.61, respectively), increased risk 1.09–1.1.50 1.27, 1.10–1.46; 1.08–1.44 1.05–1.42, respectively). only non‐anaemic (HR: 1.41, 1.18–1.1.70 1.58, 1.18‐2.12.). Furthermore, guideline HF, regardless status 1.26, 1.08–1.1.47; 1.34, 1.17–1.53). Conclusions ID, when μmol/L, status. patients.

Language: Английский

---

Ferric Carboxymaltose in Heart Failure with Iron Deficiency

New England Journal of Medicine, Journal Year: 2023, Volume and Issue: 389(22), P. 2108 - 2110

Published: Nov. 29, 2023

www.rug.nl/research/portal.For technical reasons the number of authors shown on this

Language: Английский

---